Moderna

Markets

Moderna Settles $2.25 Billion Patent Dispute, Shares Jump 10% on Legal Clarity

The biotech resolves a long-running lipid nanoparticle infringement case with Arbutus and Genevant, clearing a path for its post-COVID vaccine portfolio.

7 min read ·